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plasty—compared to non-infected patients— ranged from 5.4 to 54 days. Differences 
in populations and outcome measures in studies evaluating mortality, readmissions 
and costs due to SSIs associated with hip arthroplasty precluded group analysis. 
A representative example of results from one US study reported the average total 
charges (in 2006 US$) of treating SSIs in patients who underwent primary total hip 
arthroplasty to be $73,452 compared to $38,588 to treat non-infected patients. In 
addition, a UK study showed that treating MRSA infections further exacerbated out-
comes, with excess mean LOS of 14 days and increased costs of £4,465 compared to 
non-MRSA infections in 2004. ConClusions: SSI infections after hip arthroplasty 
impose additional cost; an important portion of SSIs are associated with S. aureus. 
An unmet need for targeted preventive strategies to reduce the consequences of 
SSIs is highlighted.
INFECTION – Patient-Reported Outcomes & Patient Preference Studies
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POOR AdhERENCE TO hCv MEdICATION IN A MEdICAId POPulATION
Kim Y.A.1, Nguyen M.2, Richards K.M.1, Wilson J.P.1, Rascati K.L.1
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objeCtives: In a real-world setting, adherence to antiviral therapies is often sub-
par and treatment outcomes are consequently compromised. This study evaluated 
the adherence rate to HCV therapy in a Medicaid population. Methods: Patients 
eligible for this study were Texas Medicaid patients ≥ 18 years who had evidence of 
chronic HCV during the identification period (1/1/07 – 9/30/11) and were continu-
ously enrolled throughout the assessment period. Primary outcome was adher-
ence to pegylated interferon (Peg-IFN) and telaprevir (TLV) or boceprevir (BOC) as 
measured by proportion of days covered (PDC) using refill history. Univariate and 
multivariate logistic regression analysis evaluated predictors for adherence, such 
as age (< 55, ≥ 55), gender, Charlson comorbidity index (CCI), race (Whites vs. Non-
Whites), presence of medical/psychosocial comorbidities, number of prescription 
drugs and office visits (intervals of 10), and evidence of adherence to other chronic 
medications (coronary artery disease and diabetes). Results: A total of 24,032 
patients were identified as having chronic HCV; 9.4% with evidence of receiving 
HCV treatment. Of those treated, 11.2% were initiated on therapy with either TLV 
or BOC in 2011. The average HCV medication PDC was 70% with a significant dif-
ference between the first 12 weeks and the following 12 weeks of therapy (79% vs. 
60%, p< 0.001). Significant positive independent predictors of HCV medication PDC 
greater than 70% included male gender (OR: 1.42, 95% CI: 1.08-1.86), higher number 
of non-HCV prescription drugs (OR: 1.11, 95% CI: 1.02-1.21) and higher number of 
outpatient visits (OR: 1.19, 95% CI: 1.08-1.31). Age, CCI, race and adherence levels 
to other chronic medications were not significant independent predictors for HCV 
medication PDC. ConClusions: Overall adherence for HCV therapy was poor 
(70%), especially after the initial 12 weeks of therapy (60%). Closer follow-up and 
management of other comorbidities may improve readiness to HCV therapy and 
improve treatment adherence.
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PNEuMOCOCCAl vACCINATION COvERAgE IN IMMuNOCOMPROMISEd AdulTS 
IN ThE uNITEd STATES
Huang M.Y., Yang H.K., Zhang D.
Merck & Co., Inc, West Point, PA, USA
objeCtives: Adults with immunocompromising conditions have higher chances 
of developing pneumococcal disease and should receive pneumococcal vaccination 
based on the recommendations by U.S. Centers for Disease Control and Prevention. 
This study examined pneumococcal vaccination in immunocompromised adults, 
including patients with chronic renal disease (CRD), cancer, HIV infection, and 
patients who underwent transplant. Methods: A large administrative claims 
database was used to assess the pneumococcal vaccination among adults aged 
19-64 years who were newly diagnosed with CRD, cancer, HIV, or patients underwent 
organ transplant procedure during 2007-2010. These patients were followed until 
2011 or the end of enrollment to identify whether they received pneumococcal vac-
cination after the diagnosis or procedure. Multivariate logistic regression was used 
to examine patients characteristics associated with pneumococcal vaccination cov-
erage. Results: We identified 22,862 patients with CRD, 216,658 with cancer, 2,576 
with HIV infection, and 41,889 patients underwent transplant procedure during the 
study period. The pneumococcal vaccination coverage were 7.3% among patients 
with newly diagnosed with CRD, 4.8% among cancer patients, 31.0% among HIV 
patients, and 5.2% among patients underwent transplant. Immunocompromised 
patients with more hospitalizations during the follow-up period had higher cover-
age, except for HIV patients. Coverage was consistently higher with more visits 
to doctor office and pharmacy across all immunocompromising conditions. The 
majority of immunocompromised patients received their vaccines at the primary 
care physician’s (PCP) office (68.4% among patients with CRD, 70.0% among can-
cer, and 75.0% among transplant) except for HIV patients (45.2% at PCP office vs. 
45.7% at specialist office). Vaccination out-of-pocket costs ranged from $3.41 (HIV) 
to $11.06(CRD) for immunocompromised patients. ConClusions: Pneumococcal 
vaccination coverage was highest in HIV patients and lowest in cancer patients 
among all immunocompromising conditions. However, even HIV population did not 
meet Healthy people 2020 target for immunocompromised patients (60%). A more 
efficient immunization strategy should be developed to improve pneumococcal 
vaccination coverage for the immunocompromised adults.
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PATIENT MANAgEMENT PROgRAMS lEAd TO IMPROvEd AdhERENCE FOR 
PATIENTS WITh hEPATITIS C uSINg dRug duAl ThERAPy IN BOTh RETAIl 
ANd CENTRAl PhARMACIES
Staskon F.1, Kirkham H.1, DuChane J.1, Moore C.2, Miller R.2, Clark B.1
1Walgreen Co., Deerfield, IL, USA, 2Walgreen Co., Carnegie, PA, USA
relative to IIV3, IIV4 is expected to avert an additional 2,516 influenza cases, 1,683 
influenza-associated medical visits, 27 influenza-associated hospitalizations and 
5 influenza-associated deaths. From a societal perspective IIV4 would generate 76 
more QALYs and a net societal budget impact of $2,265,769. The incremental cost 
effectiveness ratio (ICER) for this comparison was $29,738/QALY. 74% of simulations 
in a probabilistic sensitivity analysis were below $100,000/QALY and 29% were domi-
nant. In a scenario analysis, the ICER was $94,248 per QALY from a third party payer 
perspective. ConClusions: IIV4 is expected to achieve reductions in influenza 
related morbidity and mortality compared to IIV3. Further, despite not accounting 
for herd protection IIV4 is still expected to be a cost effective alternative to IIV3. Our 
conclusions were robust in the face of sensitivity analyses.
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uSINg BAyESIAN MOdEllINg TO ESTIMATE ThE COST EFFECTIvENESS OF 
TElAPREvIR ANd BOCEPREvIR IN ITAlIAN NAïvE PATIENTS WITh hEPATITIS C
Ruggeri M.
Università Cattolica del Sacro Cuore, Rome, Italy
objeCtives: The aim of this study is to assess the economic impact of new strate-
gies involving the administration of triple therapy (PEG IFN , ribavirin and telaprevir 
or boceprevir) to naive patients with chronic hepatitis C (CHC). Methods: eco-
nomic results were evaluated along a 30 – years time horizon. Seven health states 
were considered in our model: CHC genotype 1, sustained virologic response (SVR), 
compensated cirrhosis, decompensated cirrhosis, HCC, liver transplantation and 
death. The effectiveness of telaprevir in naïve patients was inferred from ADVANCE 
trial, whilst the effectiveness of boceprevir was inferred from the SPRINT 2 trial. 
Quality of life (QoL) scores were used to adjust the years gained by patients enrolled 
in the model. Resource consumption was estimated from the Italian SSN perspec-
tive. Costs and benefits were discounted at a rate of 3.5%. To map the uncertainty of 
the model resulting from the Bayesian analysis, a probabilistic sensitivity analysis 
was carried out. Results: In both cases the ICER is likely to be under an hypotheti-
cal threshold of € 20.000 – 30.000. However, strategy which includes treatment with 
teelaprevir is proven to have a more favorable cost effectiveness ratio.(€ 12.000 vs € 
14.000). In the case of telaprevir probability of being under the threshold of € 30.000/
QALY is 100/, whist for Boceprevir probability is 70%. ConClusions: In general, the 
provision of either telaprevir and boceprevir was proved to be affordable compared 
to the standard of care.
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ECONOMIC IMPACT OF A 13-vAlENT PNEuMOCOCCAl CONjugATE 
vACCINATION PROgRAMME IN A MExICAN CORPORATE SETTINg
Huicochea-Bartelt J.L.1, Muciño-Ortega E.1, Vargas-Valencia J.J.2
1Pfizer S.A. de C.V., Ciudad de México, Mexico, 2Econopharma Consulting S.A. de C.V., Mexico 
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objeCtives: An elevated number of absence days and disability affect both employ-
ers and employees as a result of pneumococcal diseases. This study aims to estimate 
the impact of a 13-Valent Pneumococcal vaccination program from employer´s per-
spective in a medium size Mexican-Corporate setting. Methods: A decision tree 
was built in order to estimate yearly productivity losses and absence days avoided, 
as well as pneumococcal disease treatment costs. Local incidence of pneumococ-
cal diseases as well as mortality rates were extracted from published and Mexican 
Government databases. Treatment costs were retrieved from the most representa-
tive Mexican public health care provider. The cost of the vaccine was provided by the 
manufacturer. A base scenario of a 1,000 employee company with a homogeneous 
distribution of ages (18< x< 65) was assumed to show the potential benefits of the 
program in patients between 50 and 65 years old (average monthly wage: US$779). 
Productivity losses are expressed in 2013 US$ (5% discount rate/year). A bivari-
ate sensitivity analysis of both, vaccine cost (+10%) and effectiveness (-10%) was 
performed. Results: Assuming 50% employee enrollment into the program, and 
vaccination cost split 50/50 between employer and employee, a single employer 
investment of US$50 per program participant could potentially generate savings 
of US$33 for each over a ten year horizon. We estimate 395 absence days can be 
avoided, representing avoided productivity losses as high as US$8,315 across all 
participants in ten years. The program becomes cost-saving at year 7, however 
absences are avoided from the first year. The total treatment plus productivity 
losses of an invasive infection, in- and outpatient pneumonia are respectively 54, 
34 and 47 times higher than the vaccination outlay. Outcomes were robust to a 10% 
variation in both vaccination cost and effectiveness. ConClusions: A 13-Valent 
Pneumococcal vaccination program could bring potential savings for employers 
from the seventh year of implementation.
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EPIdEMIOlOgICAl ANd ECONOMIC BuRdEN OF SuRgICAl SITE INFECTIONS 
(SSIS) ASSOCIATEd WITh hIP ARThROPlASTy
Patel H.1, Khoury H.1, Girgenti D.2, Welner S.1, Yu H.2
1LASER Analytica, Montreal, QC, Canada, 2Pfizer, Inc., Collegeville, PA, USA
objeCtives: SSIs are post-surgical complications that are associated with substan-
tial economic burden. Patients who undergo hip arthroplasty may develop SSIs, 
with seriously affected individuals typically requiring costly interventions including 
revision surgery or possibly removal of prostheses. The objective is to review the 
global epidemiology and burden of SSIs following hip arthroplasty, with a focus on 
Staphylococcus aureus (S. aureus). Methods: A comprehensive search was conducted 
in PubMed and relevant conference abstracts; 240 publications were reviewed to 
identify the epidemiology and burden of SSIs associated with hip arthroplasty pub-
lished between 2003 and 2013. Results: The median SSI infection rate as a percent 
of all hip arthroplasties was 1.8% (range: 0.05%-28%). Median 44% (18%-60%) of 
SSIs after hip arthroplasty were attributed to S.aureus. Methicillin-resistant S.aureus 
(MRSA) infection rates (% all S.aureus infections) from three studies were calculated 
as 16%, 31% and 56%, with variations in the range likely due to small sample size. 
Length of stay (LOS) prolongation for patients who developed SSIs after hip arthro-
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TETANuS TOxOId, dIPhThERIA TOxOId, ANd ACEllulAR PuERTuSSIS (TdAP) 
vACCINE COMPlIANCE AMONg AdOlESCENTS IN ThE uNITEd STATES
Kurosky S., Davis K.L., Karve S.J.
RTI Health Solutions, Research Triangle Park, NC, USA
objeCtives: Pertussis is endemic in the US despite recommendations for rou-
tine vaccination. Recent evidence suggests waning immunity among adolescents 
is one catalyst for the spread of disease. Although 89% of adolescents received 
Td/Tdap vaccine in 2012, little is known about coverage of pertussis containing 
vaccination specifically, or if Tdap is administered at age-appropriate times (age 
10 to 12 years). We sought to evaluate coverage and age-appropriate Tdap receipt 
among adolescents in the US. Methods: Participant reported demographics and 
immunization provider reported vaccinations were analyzed from the 2010 and 
2011 National Immunization Survey-Teen. Among children aged 13 to 17 years, we 
assessed the proportion who received at least one dose of Tdap (coverage) and the 
age at administration (age-appropriate receipt). Among those who received Tdap, 
we estimated multivariable logistic regression models to identify factors associated 
with age-appropriate vaccination. Results: Between 2010 and 2011, the propor-
tion of adolescents who received at least one Tdap vaccination between the ages 
of 10 to 17 increased from 64.3% to 73.8%, respectively (p< 0.0001). Among those 
who received Tdap, 61.6% in 2010 to 71.3% in 2011 received age-appropriate vac-
cination (p< 0.0001). Among those who delayed Tdap vaccination, the mean age of 
vaccination was approximately 14 years in both 2010 and 2011. Among adolescents 
who received Tdap, having a mother with more than 12 years of education (OR= 1.2, 
p< 0.0001) increased the likelihood of age-appropriate vaccination. Whereas, not 
having an adolescent well-child visit (OR= 0.46, p< 0.0001), having multiple vacci-
nation providers (OR= 0.85, p< 0.0001), and having a gap in health insurance cover-
age (OR= 0.72, p= 0.0004) significantly decreased the likelihood of age-appropriate 
vaccination. ConClusions: Coverage and age-appropriate receipt of Tdap among 
adolescents is suboptimal, yet improving. Overall, two-thirds of adolescents received 
Tdap, of which 29% to 38% received it after the recommended age, on average leaving 
two years during which pertussis immunity may have waned.
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PERSISTENCE ON ANTIRETROvIRAl ThERAPy IN WOMEN ENROllEd IN ThE 
WIhS COhORT: 1998-2013
Hardy H.1, Rosenblatt L.1, Shi Q.2, Hoover D.R.3, Young M.4, Golub E.5, Greenblatt R.6, 
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objeCtives: To assess persistence on protease inhibitors [PI; atazanavir/ritonavir 
(ATV±r), lopinavir/r (LPV/r), darunavir/r (DRV/r)]- or efavirenz (EFV)-based antiretro-
viral therapy (ART)] in the Women’s Interagency HIV Study (WIHS), a large, US, obser-
vational cohort. Methods: This retrospective analysis of WIHS used bi-annually 
collected data from January 1998-April 2013. HIV+ women initiating ATV±r, LPV/r, 
DRV/r or EFV were followed until discontinuation of the index PI or EFV, dropout 
from cohort, or end of study period. Persistence on ATV±r, LPV/r, DRV/r or EFV over 
50 months stratified by prior ART experience (ART naive, 0-1 prior PI, ≥ 2 prior PIs) 
was analyzed using Kaplan-Meier curves. In the analysis, we considered patient 
baseline variables (demographics, co-morbidities, viral load, CD4, and depression/ 
quality of life and ART regimens used prior to initiating the index PI or EFV), and 
follow-up variables (adherence, reasons for ART discontinuation). Results: In total, 
661 women initiated ATV±r, 546 LPV/r, 203 DRV/r and 815 EFV-based regimens. Mean 
age was 41 years, > 50% were Black, > 15% were HCV+ and > 50% had prior illicit drug 
use. For women with no prior ART, persistence at 50 months was 54% for EFV, 53% 
for ATV±r, and 14% for LPV/r (P = 0.0015); DRV/r had unreliable data in ART-naïve 
due to small sample size). For ART exposed women with 0-1 PI, persistence was 64% 
for DRV/r, 50% for ATV±r, 49% for EFV, and 29% for LPV/r (P < 0.0001). For women 
with ≥ 2 prior PI exposure, persistence was 70% for DRV/r, 41% for ATV±r, 28% for 
LPV/r, and 23% for EFV (P < 0.0001). ConClusions: Persistence differed among the 
ART regimens in analyses that stratified by prior ART/PI experience. Proportional 
hazards regression will be used to examine if case-mix differences contribute to 
these patterns.
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REAl-WORld PERSISTENCE WITh SINglE vERSuS MulTIPlE TABlET 
REgIMENS FOR hIv-1 TREATMENT
Sweet D.E.1, Kim Y.2, Song J.3, Zhong Y.3, Signorovitch J.3
1The University of Kansas School of Medicine – Wichita, Wichita, KS, USA, 2Gilead Sciences, Inc., 
Foster City, CA, USA, 3Analysis Group, Inc., Boston, MA, USA
objeCtives: Non-persistent use of any component of an antiretroviral (ARV) regi-
men can lead to viral replication and treatment resistance. We compared real-
world persistence between HIV-1 infected patients receiving once-daily single 
tablet regimens (STRs) versus multiple-tablet regimens (MTRs) using 7-year his-
tory in a claims database. In addition, we assessed whether initial MTR persis-
tence predicted long-term persistence comparable to an STR. Methods: HIV-1 
infected patients filling ARV prescriptions after a 90-day washout were identified 
in a large claims database (07/2006-03/2013). Index regimens were classified as 
STRs (1 pill daily) or MTRs (≥ 2 pills daily). Persistence was measured as the time 
from starting the index regimen to the first 90-day prescription gap for any ARV 
in the index regimen, or to the first prescription for an ARV not in the index 
regimen. Persistence was compared between STRs and MTRs with a logrank test. 
Additionally, the subgroup persistent on MTRs for the first 6 months was compared 
to the full group receiving STRs and the subgroup persistent on STRs for the first 6 
months. Results: Among 3,590 patients who initiated ART, 1,909 (53%) patients 
objeCtives: The study investigated the longitudinal effect of pharmacy manage-
ment programs on adherence rates for patients using dual therapy for the hepatitis 
C virus (HCV) within retail and central pharmacy channels. Methods: This was a 
retrospective study of patients new to HCV therapy, who used either retail or central 
pharmacy channels to obtain their HCV prescriptions. Although the two channels 
had different operational structures, they provided similar patient management ser-
vices. The adherence metric was the proportion of days covered (PDC), as endorsed 
by the Pharmacy Quality Alliance. Active involvement with a patient management 
program for at least 90 days was examined as a predictor for adherence. Due to the 
different managed therapy models across channels, propensity scores were used 
to match patients for the retail analysis, and analysis of covariance was used for 
the central analysis. Results: Mean PDC rates for the retail patients improved 
significantly (16.2%, p < 0.0001) for patients managed at least 90 days compared to 
those less managed. Similarly, patients managed at least 90 days within the central 
distribution channel had significantly higher adherence rates (29.4%, p < 0.0001) 
than those who did not remain managed. Among retail patients managed at least 
90 days, the mean adherence level (77.9%) was comparable (i.e., not significantly 
different) to that of the central patients (76.8%). The proportion of patients who 
were adherent to medications (PDC ≥ 80%) indicated similar significant trends as 
for mean PDC. ConClusions: Pharmacy services increased adherence to HCV dual 
therapy medications in both central and retail pharmacy channels, and reduced the 
difference in adherence between channels. Previous research has linked medica-
tion adherence to reduced viral loads from drug therapy, and improved clinical 
outcomes. Providing HCV pharmacy management programs that address patient 
adherence to therapy will likely improve the long-term health outcomes for these 
patients.
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FACTORS AFFECTINg AdhERENCE WITh hIv TREATMENT guIdElINES
Villacorta R.1, Han X.1, Clark B.2, Hou J.G.3, Miner P.A.4, McCombs J.1
1University of Southern California, Los Angeles, CA, USA, 2Walgreen Co., Deerfield, IL, USA, 
3Walgreens Co., Deerfield, IL, USA, 4Gilead Sciences, Inc., Foster City, CA, USA
bACkgRound: Compliance with HIV treatment guidelines has not been studied in 
a large sample of real-world patients. objeCtives: Document the impact of guide-
lines and patient characteristics on adherence. Methods: Prescription drug data 
from a national retail pharmacy chain were used to identify new episodes of HIV 
therapy initiated between January 1, 2008 and July 31, 2012. The mix of medications 
used as initial therapy was defined using a 4 days window following the fill date of 
the initial HIV prescription. All episodes were screened for 6 months of data with no 
prior HIV prescriptions and for one year of post data. Patient characteristics included 
age, gender, state of residence and health insurance type. Regimens were classified 
according to the United States (US) Department of Health and Human Services (DHHS) 
treatment guidelines. Adherence was measured as the proportion of days covered 
[PDC] and PDC≥ 90%. Results: 113,933 episodes met study criteria. Patients were 
predominately male and between ages 35 and 55. Average PDC was 41.4% and only 
16.2% of patients achieved PDC≥ 90%. Multivariate analyses found that adherence 
increased monotonically with age and with male gender. Nearly 43% of patients used 
a DHHS preferred regimen and achieved significantly better adherence. Patients were 
less adherent when ritonavir was added to the treatment regimen. Using the single 
tab DHHS preferred regimen increased the likelihood of achieving PDC≥ 90% [Odds 
ratio = 1.23; (1.16-1.30)]. Patients using non-DHHS guideline regimens were less likely 
to be adherent though their PDC increased monotonically with the number of drugs 
used. ConClusions: The quality of HIV drug therapy in the US is mixed. While 59% 
of patients use a DHHS approved regimen, 30% of patients used only a single medi-
cation. Just over 16% of patients achieved a PDC of ≥ 90%. However, this goal is more 
likely to be achieved when prescribing follows treatment guidelines.
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glOBAl PNEuMOCOCCAl vACCINATION IN EldERly: A SySTEMATIC 
lITERATuRE REvIEW
Huang M.Y., Yang H.K.
Merck & Co., Inc, West Point, PA, USA
objeCtives: Elderly population has a higher chance of developing pneumococcal 
disease and is recommended to receive pneumococcal vaccination by government 
agencies around the world. In the U.S., CDC reports pneumococcal vaccination 
coverage in the elderly annually. However, the pneumococcal vaccination coverage 
in elderly outside of the U.S. is unclear. The objective of this study was to review 
published data on the current global pneumococcal vaccination. Methods: A 
systematic literature review was conducted in PubMed/MEDLINE to identify stud-
ies published between 2011-2013 that have assessed pneumococcal vaccination 
coverage in elderly population aged 65 years or older. Results: Thirty-nine stud-
ies that assessed pneumococcal vaccination among elderly were identified, with 
16 from North America (NA), 11 from Western Europe (WE), 7 from Asia Pacific 
(AP), 3 from Latin America (LA), and 2 from the Middle East (ME). No studies were 
found in Eastern Europe (EE) and Africa. Around 70% of identified studies were 
from NA and WE, where most governments have recommended pneumococcal 
vaccines for elderly. While many countries in AP, LA, and EE have similar recom-
mendations, only a few countries have conducted studies to assess the vaccination 
coverage to explore the policy uptake. Limited countries in Africa and ME have 
national recommendations, which could be the reason why the related research 
has been scant. Overall, 15 studies explored pneumococcal vaccination for general 
older population, while the rest (n= 24) assessed coverage for elderly with certain 
conditions or sociodemographic characteristics, or in specific settings. Population-
based studies showed that the pneumococcal vaccination coverage in elderly 
ranged 49.8%-68.6% for NA (n= 5),36.4%-50.9% for WE (n= 2),18.4%-61.0% for AP 
(n= 5),8.7%-44.3% for LA (n= 2), and 72% for Israel (n= 1). ConClusions: Limited 
data on pneumococcal vaccination in elderly were reported for countries in LA, AP, 
EE, ME, and Africa regions. Further studies that examine pneumococcal vaccina-
tion in these regions are needed to evaluate the implementation of related policy.
